23andMe cuts 40% of its workforce and discontinues therapeutics division
The company said it plans to wind down ongoing clinical trials “as quickly as practical” — and that ... since — particularly with most buyers of its saliva-based testing kits only needing to purchase once. The company reported a net loss of $ ...
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.
23andMe to Cut 40% of Its Staff Amid Grim Financials
The DNA testing kit company is also discontinuing new developments to its therapeutics program, which has been focused on using customers’ DNA data to aid in drug discovery.
23andMe cuts 40% of staff in restructuring
Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. The genetic testing company is also discontinuing its therapeutics business and winding down its clinical trials;
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.
23andMe Slashes Workforce By 40%, Ends Therapeutic Programs
Genetic testing company 23andMe announced that it would be slashing its workforce by 40%, which would mean rendering 200 employees jobless, as part of its restructuring initiative to cut costs. In a press release on Monday,
23andMe to slash 40% of workforce as it restructures and shutters therapeutics division
Bay Area genetic testing company 23andMe announced Monday that it plans to lay off 40% of its workforce as part of a broader restructuring effort aimed at cutting costs and refocusing the company on its core business.
Orange County Register4h
Genetic testing giant 23andMe cuts 40% of workforce, discontinues therapeutics division
The company said it plans to wind down ongoing clinical trials “as quickly as practical” — and that ... since — ...
Hosted on MSN9h
After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health
Hit by a slowing demand for its flagship DNA-testing kit, 23andMe also contended with a massive data ... and asset sales of ...
Yahoo Finance1d
Everest Biolabs - Elevating exosome research with new tools to accelerate the development of clinical applications
The Atlas ELISA kits and Atlas ... the potential of EVs in clinical applications, we keep 'science first' while fostering ...
labmate-online.com11d
New laminin isoform kit simplifies cell culture workflow
AMSBIO has launched the iMatrix Palette, a comprehensive kit designed to streamline cell culture and differentiation ...
Business Insider11h
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025
while continuing to use our GraftAssure test kit to perform research. Of note, our GraftAssure research product may not be used to support clinical treatment decisions. We are pleased with our ...
GEN7d
Patient Dies in Beam Trial of SCD Candidate; Company Cites Conditioning
The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...
manilatimes12d
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a ...
Strategic Focus and Growth Potential Drive Buy Rating for Veracyte
Veracyte (VCYT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Puneet Souda ...